DiaMedica Therapeutics Announces Inclusion in the Russell 2000 ® and Russell 3000 ® Indexes
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke, today announced its upcoming addition as a member of the US small-cap Russell 2000 and Russell 3000 Indexes, effective after the U.S. market closes on June 27.
The Russell 3000 Index encompasses the 3,000 largest U.S. companies by market capitalization, representing approximately 98% of the investable U.S. equity market. The Russell 2000 Index is a subset of the Russell 3000, measuring the performance of the small-cap segment. These indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies.
'DiaMedica's inclusion in the Russell 2000 and Russell 3000 indexes marks an important milestone in our company's journey,' said Rick Pauls, President and CEO of DiaMedica. 'This recognition enhances our visibility among the broader investment community, supports increased institutional interest and ownership in our stock and serves as strong validation of our team's ability drive value for our shareholders.'
DM199 for Preeclampsia KOL Replay
DiaMedica also recently hosted a preeclampsia webinar featuring Prof. Baha Sibai, MD (University of Texas) Prof. Stephen Tong, MD, PhD (The University of Melbourne), Prof. Susan Walker, MD, PhD (The University of Melbourne), and who discussed the unmet need and current treatment landscape for preeclampsia (PE), a life-threatening pregnancy associated vascular disorder with no approved therapeutics. The Company plans to announce top-line Phase 2 results by mid-July. Click this link to listen to the replay
About DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from preeclampsia and acute ischemic stroke. DiaMedica's lead candidate, DM199, is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of acute ischemic stroke, preeclampsia and other vascular diseases. For more information visit the Company's website at www.diamedica.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
25 minutes ago
- Business Wire
U.S. Navy Orders $2.0M in LRAD by Genasys Maritime Communication Systems
SAN DIEGO--(BUSINESS WIRE)-- Genasys Inc. (NASDAQ: GNSS), the global leader in Protective Communications, today announced a $2.0 million LRAD maritime systems order from the U.S. Navy (Navy). The follow-on order is part of the Navy's ongoing replacement of first generation LRADs with new LRAD 1000Xi extended range communication and ship protection systems. The order is scheduled for delivery this fiscal year. 'The LRAD 1000Xi systems are slated for deployment on Navy surface combatants, large amphibious ships, and aircraft carriers,' said Richard Danforth, Chief Executive Officer of Genasys. 'LRADs have provided Navy ships with extended range, over-water communication and scalable escalation of force capabilities for more than 20 years. LRADs enhance operational effectiveness, strengthen ship self-defense, and improve safety on Navy and Coast Guard ships whether in port or deployed.' The U.S. Military and more than 30 international Navies and Coast Guards deploy LRADs for a variety of missions and operations, including ship-to-ship communication, establishing vessel exclusion zones and restricted areas, interceptions and interdictions, search and rescue, environmental responses, coastal water control, port and shore side security, anti-piracy, maritime immigration encounters, and more. The LRAD 1000Xi features rugged military construction for reliable operation in extreme maritime conditions. By broadcasting audible hails, warnings, and commands that are clearly heard and understood over wind, engine, and background noise out to 3,000 meters, the LRAD 1000Xi provides more time and distance to communicate, determine intent, de-escalate dangerous situations, and save lives. About Genasys Inc. Genasys Inc. (NASDAQ: GNSS) is the global leader in Protective Communications. Incorporating the most comprehensive portfolio of preparedness, response, and analytics software and systems, as well as the Company's Long Range Acoustic Devices® (LRAD®) the Genasys Protect platform is designed around one premise: ensuring organizations and public safety agencies are 'Ready when it matters™.' Protecting people and saving lives for over 40 years, Genasys covers more than 155 million people in all 50 states and in over 100 countries worldwide. For more information, visit Forward-Looking Statements Except for historical information contained herein, the matters discussed are forward-looking statements within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. You should not place undue reliance on these statements. We base these statements on particular assumptions that we have made in light of our industry experience, the stage of product and market development as well as our perception of historical trends, current market conditions, current economic data, expected future developments and other factors that we believe are appropriate under the circumstances. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those suggested in any forward-looking statement. The risks and uncertainties in these forward-looking statements include without limitation the business impact of geopolitical conflicts and other causes that may affect our supply chain, and other risks and uncertainties, many of which involve factors or circumstances that are beyond the Company's control. Risks and uncertainties are identified and discussed in our filings with the Securities and Exchange Commission. These forward-looking statements are based on information and management's expectations as of the date hereof. Future results may differ materially from our current expectations. For more information regarding other potential risks and uncertainties, see the 'Risk Factors' section of the Company's Form 10-K for the fiscal year ended September 30, 2024. Genasys Inc. disclaims any intent or obligation to publicly update or revise forward-looking statements, except as otherwise specifically stated.
Yahoo
25 minutes ago
- Yahoo
Nasdaq 100 notches first record high close since February
(Reuters) -The Nasdaq 100 notched a record high close on Tuesday for the first time since February, rebounding from deep losses in recent months related to worries about U.S. President Donald Trump's global tariffs. The index, which includes 100 of the most valuable non-financial companies listed on the Nasdaq stock exchange, rose 1.5% to end at 22,190.52 as investors welcomed a fragile truce between Israel and Iran. Its previous record high close was 22,175.60 on February 19. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
29 minutes ago
- Business Wire
Bridgewater Bancshares, Inc. Completes Private Placement of
BUSINESS WIRE)--Bridgewater Bancshares, Inc. (Nasdaq: BWB) (the 'Company'), the parent company of Bridgewater Bank, today announced the completion of a private placement of $80.0 million in aggregate principal amount of 7.625% Fixed-to-Floating Rate Subordinated Notes due 2035 (the 'Notes'). The Company intends to use the net proceeds of the private placement of the Notes to redeem $50.0 million of outstanding 5.25% Fixed-to-Floating Rate Subordinated Notes due 2030 and for general corporate purposes. The Notes will initially bear interest at an annual rate of 7.625% from June 24, 2025 to June 30, 2030, with interest during this period payable semi-annually in arrears. From June 30, 2030 to the stated maturity date or early redemption date, the interest rate will be reset quarterly to an annual floating rate equal to the then current three-month term Secured Overnight Financing Rate (SOFR) plus 388 basis points, with interest during this period payable quarterly in arrears. The Notes are redeemable by the Company, in whole or in part, on or after June 30, 2030, and at any time upon the occurrence of certain events. The Notes have been structured to qualify as Tier 2 capital for the Company for regulatory capital purposes. Piper Sandler & Co. acted as lead placement agent while D.A. Davidson & Co. and Hovde Group, LLC acted as co-placement agents for the Notes offering. Barack Ferrazzano Kirschbaum & Nagelberg LLP served as legal counsel to the Company and Alston & Bird LLP served as legal counsel to the placement agents. The Notes have not been registered under the Securities Act of 1933, as amended, or any state securities laws and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. This press release is for informational purposes only and shall not constitute an offer to sell, or the solicitation of an offer to buy any security, nor shall there be any sale in any jurisdiction in which such an offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. The indebtedness evidenced by the Notes is not a deposit and is not insured by the Federal Deposit Insurance Corporation or any other government agency or fund. About Bridgewater Bridgewater Bancshares, Inc. (Nasdaq: BWB) is a St. Louis Park, Minnesota-based financial holding company founded in 2005. Its banking subsidiary, Bridgewater Bank, is a premier, full-service bank dedicated to providing responsive support and simple solutions to businesses, entrepreneurs, and successful individuals across the Twin Cities. Bridgewater offers a comprehensive suite of products and services spanning deposits, lending, and treasury management solutions. Bridgewater has also received numerous awards for its banking services and esteemed corporate culture. With total assets of $5.1 billion and nine strategically located branches as of March 31, 2025, Bridgewater is one of the largest locally-led banks in Minnesota and is committed to being the finest entrepreneurial bank. For more information, please visit Forward-Looking Statements This press release includes 'forward-looking statements' within the meanings of the Private Securities Litigation Reform Act of 1995, including but not limited to statements about the anticipated use of net proceeds from the offering and other matters. Forward-looking statements are subject to known and unknown risks and uncertainties, many of which may be beyond the Company's control. The Company cautions you that the forward-looking statements presented in this Report are not a guarantee of future events, and that actual events may differ materially from those made in or suggested by the forward-looking information contained in this Report. Forward-looking statements generally can be identified by the use of forward-looking terminology such as 'may,' 'might,' 'should,' 'could,' 'predict,' 'potential,' 'believe,' 'expect,' 'continue,' 'will,' 'anticipate,' 'seek,' 'estimate,' 'intend,' 'plan,' 'projection,' 'would,' 'annualized,' 'target' and 'outlook,' or the negative version of those words or other comparable words of a future or forward-looking nature. Factors that may cause actual results to differ materially from those made or suggested by the forward-looking statements contained in this press release include those identified in the Company's most recent annual report on Form 10-K and subsequent filings with the Securities and Exchange Commission. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
